<italic>ADCY9</italic> Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
MLA
Nissen, Steven E., et al. “ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.” JAMA Cardiology, vol. 3, no. 5, May 2018, pp. 401–08. EBSCOhost, https://doi.org/10.1001/jamacardio.2018.0569.
APA
Nissen, S. E., Pillai, S. G., Nicholls, S. J., Wolski, K., Riesmeyer, J. S., Weerakkody, G. J., Foster, W. M., McErlean, E., Li, L., Bhatnagar, P., Ruotolo, G., & Lincoff, A. M. (2018). ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study. JAMA Cardiology, 3(5), 401–408. https://doi.org/10.1001/jamacardio.2018.0569
Chicago
Nissen, Steven E., Sreekumar G. Pillai, Stephen J. Nicholls, Kathy Wolski, Jeffrey S. Riesmeyer, Govinda J. Weerakkody, Wendra M. Foster, et al. 2018. “ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.” JAMA Cardiology 3 (5): 401–8. doi:10.1001/jamacardio.2018.0569.